Biokin raises $150M in sci-tech bonds to fund oncology push
What's the deal? Sichuan Biokin PharmaceuticalDealroom has a profile for this one. Try Dealroom → has raised US$137.5M through its first 2026 issue of sci-tech innovation bonds. The post-IPO debt carries a 1.90% coupon and a 5+5-year structure, giving the drugmaker long-term funding without issuing equity.
What's the endgame? Biokin is advancing an oncology pipeline through multiple late-stage trials, including Phase III programs for its antibody-drug conjugate (ADC) candidates. Its lead drug, iza-bren, drew attention after a Phase III trial met its primary endpoint.
Why now? Clinical development is expensive, and the low stated coupon lets Biokin finance the push cheaply. The bond follows roughly US$512.9M raised in a 2025 share placement, making debt a further financing channel rather than a first capital infusion.
The signal: The issuance sits within a fast-growing market, with China reporting roughly US$412.5B of sci-tech innovation bonds since the program launched in May 2025. For Biokin, the raise is strategic — funding an expensive clinical push, not evidence by itself of a change in its prospects.
Read more: in.marketscreener.com
Image credit: foteih
